

Structural Basis of Regulation of von Willebrand Factor Binding to Glycoprotein Ib*

Received for publication, September 3, 2013, and in revised form, December 20, 2013. Published, JBC Papers in Press, January 3, 2014, DOI 10.1074/jbc.M113.511220

Mark A. Blenner¹, Xianchi Dong, and Timothy A. Springer²

From the Program in Cellular and Molecular Medicine, Boston Children's Hospital and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115

Background: Force in fluid flow regulates von Willebrand factor (VWF) A1 domain binding to glycoprotein Ib α (GPIb α).

Results: X-ray crystal structures of high affinity A1-GPIb α complexes and mutations reveal interactions involving central leucine-rich repeats of GPIb α .

Conclusion: Structural changes are on a pathway to a force-induced super high affinity state.

Significance: A1-GPIb α complexes provide insight into mechanobiology of bleeding disorders.

Activation by elongational flow of von Willebrand factor (VWF) is critical for primary hemostasis. Mutations causing type 2B von Willebrand disease (VWD), platelet-type VWD (PT-VWD), and tensile force each increase affinity of the VWF A1 domain and platelet glycoprotein Ib α (GPIb α) for one another; however, the structural basis for these observations remains elusive. Directed evolution was used to discover a further gain-of-function mutation in A1 that shifts the long range disulfide bond by one residue. We solved multiple crystal structures of this mutant A1 and A1 containing two VWD mutations complexed with GPIb α containing two PT-VWD mutations. We observed a gained interaction between A1 and the central leucine-rich repeats (LRRs) of GPIb α , previously shown to be important at high shear stress, and verified its importance mutationally. These findings suggest that structural changes, including central GPIb α LRR-A1 contact, contribute to VWF affinity regulation. Among the mutant complexes, variation in contacts and poor complementarity between the GPIb α β -finger and the region of A1 harboring VWD mutations lead us to hypothesize that the structures are on a pathway to, but have not yet reached, a force-induced super high affinity state.

von Willebrand factor (VWF)³ is a plasma glycoprotein with monomers that are 2,050 residues in length and are linked head-to-head and tail-to-tail into ultralong concatemers. VWF senses exposure of the subendothelium and changes in flow at

sites of bleeding and is required for hemostasis in the rapid flow of the arteriolar circulation (1–5). VWF binds through its A1 domain to the GPIb α subunit of the GPIb-GPIX complex on platelets. No interaction between VWF and GPIb α is seen in stasis or in low flow; however, above a threshold flow, they bind and mediate *in vivo* platelet plug formation and *in vitro* aggregation of platelets in stirred cuvettes and rolling of platelets on VWF immobilized on the walls of flow chambers (6). Multiple mechanisms are thought to contribute to enhancement of VWF adhesiveness by flow. One mechanism by which flow can activate VWF is induction of transition from a bird's nest to an elongated conformation, leading to better exposure of the VWF monomers for multimeric binding to platelets (7).

Conformational change within the A1 domain of VWF and platelet glycoprotein Ib α is the second postulated mechanism for regulating their interaction (8). In flow, the hydrodynamic force exerted on VWF multimers results in tensile force exerted throughout the multimer at the connections between neighboring domains (*e.g.* on the N and C termini of the A1 domain). The force exerted near the middle of a long VWF multimer free in shear flow has been estimated to reach 10 pN, and it would be much higher for VWF in elongational flow or bound to the vessel wall at a site of hemorrhage (5, 9). Named after the three A domains in VWF, VWA domains (or VWA folds) are widely distributed and also appear in integrins as the inserted domains in their α and β subunits (*i.e.* the integrin α I and β I domains). As a VWA domain, A1 has largely alternating β -strands and α -helices that assemble into a Rossman-like fold with a central β -sheet surrounded by amphipathic α -helices (10). In integrin VWA (α I and β I) domains, a 10-Å axial displacement of the C-terminal α -helix is linked to communication of allostery to a neighboring domain and to a change in conformation at the metal ion-dependent adhesion site where ligand is bound (11). However, the A domains in VWF contain no bound metal ion, and GPIb α binds at a completely different site on A1 to the edge of the central β -sheet rather than to the turns between β -strands and α -helices at the C-terminal end of the β -sheet (12, 13).

Mutations in VWF are the most frequent cause of heritable bleeding disorders and provide important insights into function. Interesting gain-of-function mutations in von Willebrand

* This work was supported, in whole or in part, by National Institutes of Health Grant HL-103526 and Postdoctoral Fellowship NIH-1F32HL-099167 (to M. A. B.). This work was also supported by American Heart Association Postdoctoral Fellowship AHA-10POST4170043 (to M. A. B.).

The atomic coordinates and structure factors (codes 4C2A, 4C2B, and 4C29) have been deposited in the Protein Data Bank (<http://www.pdb.org/>).

¹ Present address: Dept. of Chemical and Biomolecular Engineering, Clemson University, Earle Hall Rm. 207A, Clemson, SC 29634.

² To whom correspondence should be addressed: Program in Cellular and Molecular Medicine, Boston Children's Hospital and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 3 Blackfan Circle, Boston, MA 02115. Tel.: 617-713-8200; Fax: 617-713-8232; E-mail: timothy.springer@childrens.harvard.edu.

³ The abbreviations used are: VWF, von Willebrand factor; GPIb α , glycoprotein Ib α ; VWD, von Willebrand disease; PT-VWD, platelet-type VWD; LRR, leucine-rich repeat; pN, piconewtons; PDB, Protein Data Bank.

disease (VWD) type 2B localize to the region of A1 in or adjacent to the ordered N- and C-terminal segments, distal to the binding site for platelet GPIIb α . Therefore, it has been suggested that these mutations might release A1 from a lower affinity conformation (10, 12). Notably, the sites of these mutations are near the termini where elongational force in VWF multimers is exerted on A1.

Gain-of-function mutations in platelet type VWD (PT-VWD) locate in GPIIb α and have a phenotype similar to VWD type 2B mutations in VWF A1. GPIIb α has an N-terminal leucine-rich repeat (LRR) domain with eight LRRs and N- and C-terminal segments that cap the LRRs (10). A partially ordered β -switch region in the C-terminal cap of GPIIb α becomes ordered upon binding to A1 and forms a β -hairpin with two β -strands that add onto the central VWA β -sheet (12). GPIIb α VWD mutations all map to the β -switch and are thought to favor the β -strand conformation found in the bound state over a disordered or α -helical state found in the unbound state (12–14).

Crystal structures of the A1 and GPIIb α complex show two discontinuous binding interfaces, whether the components are wild-type or contain gain-of-function A1-R1306Q and GPIIb-M239V mutations (12, 13). Differences were seen between wild-type and gain-of-function complexes in the N and C termini and α 1- β 2 loop of A1. However, no compelling gained interactions were seen in the gain-of-function mutant complex that could explain its higher affinity, and it has remained unclear how the affinity of A1 and GPIIb α for one another could be regulated by hydrodynamic flow. Thus, in contrast to integrin I domains, an allosteric mechanism for regulating affinity of A1 and GPIIb α for one another remains unclear.

Two types of evidence for force-induced conformational change in the A1-GPIIb α complex motivated the current study. Chimeras between human and canine GPIIb α showed that the LRRs between the two discontinuous contacts with A1 were unimportant at low shear but became important at high shear (15, 16). Measurements on a receptor and ligand in a single molecule (ReaLiSM) construct in which A1 was connected at its C terminus through a polypeptide linker to the N terminus of GPIIb α revealed reversible unbinding and rebinding (8). Two distinct pathways of force-dependent dissociation were found. The kinetics of force-dependent dissociation (k_{off}) of the two pathways were well fit by biophysical models that relate k_{off} to k_{off}^0 in the absence of force (k_{off}^0) and the exponential of tensile (elongational) force. A complex with faster k_{off}^0 predominated below a force of 10 pN, and a complex with a slower k_{off}^0 and lesser exponentiation by force predominated above 10 pN, suggesting two conformational states of the receptor-ligand complex (8).

Here, we use crystallographic structures and mutations to address the principles that regulate affinity of A1 and GPIIb α for one another. Moving beyond the use of one gain-of-function mutation in A1 and one in GPIIb α (12), we use a total of four VWD gain-of-function mutations, two each in A1 and GPIIb α . Using directed evolution in yeast, we discover further gain-of-function mutations in A1. Shifting the long range disulfide bond in A1 by one residue in sequence causes a large increase in affinity. We describe the structure of this mutant alone and

complexed with GPIIb α containing two VWD mutations. In our high affinity structures, a gained interaction is found in the region implicated in GPIIb α chimeras as important at high shear stress (15) and is found to be important in mutational experiments. Structural analysis of the region harboring gain-of-function mutations in A1 suggests clashing rather than complementary interactions with the GPIIb α β -finger and leads us to suggest that our structures are on a pathway to, but have not yet reached, a hypothetical force-induced super high affinity state.

EXPERIMENTAL PROCEDURES

Protein Expression and Purification—The cDNA sequence encoding VWF A1 (Glu¹²⁶⁴–Leu¹⁴⁶⁹) was cloned into the pET21a vector with an initiation Met codon and expressed in BL21(DE3) cells (17). Gain-of-function mutations were introduced using QuikChange (Stratagene). Refolding was performed essentially as described (17). Refolded A1 was purified with nickel-nitrilotriacetic acid beads (Qiagen), followed by a heparin-Sepharose affinity column (GE Healthcare), and a S75 gel filtration column (GE Healthcare). The cDNA for human platelet GPIIb α (His¹–Arg²⁹⁰) was mutated using QuikChange (Stratagene). For crystallization, two N-linked glycosylation sites were removed with N21R and N159R mutations. GPIIb α mutants were cloned into an ET-6 vector, which resembles ET-1 (18), except it contains only a C-terminal His₆ tag. Stable transfectants were established in HEK293T cells. Protein was expressed in 293 Freestyle medium (Invitrogen) and initially purified using an anti-GPIIb α IgG-Sepharose column. Monoclonal antibody 12E4 (19) was coupled to cyanogen bromide-activated Sepharose 4B FF (GE Healthcare) using the manufacturer's protocols. Culture medium supernatant was flowed over 12E4-Sepharose and eluted with 0.1 M glycine, pH 2.4, and immediately neutralized with one-quarter volume of 1 M Tris, pH 8.5. GPIIb α was further purified on a S200 gel filtration column (GE Healthcare).

Yeast Surface Display—The cDNA sequence encoding the above A1 fragment was cloned into the pCTCON2 yeast surface display plasmid in frame with Aga2-HA tag and with the C-terminal c-Myc tag. A1 random libraries were created using nucleotide analog PCR (20) and transformed into *Saccharomyces cerevisiae* strain EBY100 by electroporation (21). Library complexity was greater than 10⁷ unique clones. Expression was induced using synthetic galactose medium with casamino acids (SGCAA), and 10⁹ yeasts were sorted by magnetic activated cell sorting (LS Columns, Miltenyi Biotec) for functional expression using 200 nM biotinylated GPIIb α prepared with EZ-Link NHS-PEG4-Biotin (Pierce) and coated onto anti-biotin magnetic beads (Miltenyi Biotec). The functional library was then regrown and sorted twice by fluorescence-activated cell sorting (FACS) with 50 nM biotinylated GPIIb α detected with streptavidin-phycoerythrin (Invitrogen); and with a 1:100 dilution of 9E10 anti-c-Myc antibody (Covance) detected with FITC-labeled anti-mouse IgG (Invitrogen). The sorting gate was selected for improved apparent affinity. Last, the library was sorted for decreased off-rate by competition with 10 μ M non-labeled GPIIb α for 4 h before sorting for cells retaining fluorescence. Fourteen recovered clones were sequenced.

Flow cytometry of yeast was performed on a FACScan (BD Biosciences). 10^5 yeasts were harvested, washed three times in room temperature PBS + 1% BSA (PBSB), and incubated with 50 nM biotinylated GPIIb α and anti-c-Myc 9E10 IgG (1:200) at room temperature for 1 h. Cells were then centrifuged and washed three times in ice-cold PBSB before incubation with secondary reagents (1:200 dilution of streptavidin-phycoerythrin and 1:100 dilution of FITC-labeled goat anti-mouse IgG) for 20 min at 4 °C. 10^4 yeasts were analyzed for mean fluorescence intensity for both GPIIb α and c-Myc. The specific fluorescence intensity was calculated by subtracting autofluorescence from uninduced controls. Because the fluorescence signal is affected by both affinity and surface expression, we calculate the adjusted specific fluorescence intensity by dividing the specific fluorescence intensity from the GPIIb α signal by the specific fluorescence intensity from c-Myc and normalizing to WT (WT adjusted specific fluorescence intensity = 1). Single mutations of A1 expressed using yeast display were generated using QuikChange mutagenesis.

Radioligand Binding Experiments—Purified high affinity GPIIb α containing PT-VWD mutations G233V and M239V (GPIIb α /VWD2) was radioiodinated using the IODO-GEN method (Pierce). 250 μ g of purified protein was iodinated with 1 mCi of Na¹²⁵I radionuclide (PerkinElmer Life Sciences) for 20 min at room temperature. The reaction was quenched with 2 mg/ml L-tyrosine for 5 min. After the addition of 5 mM potassium iodide, the radiolabeled GPIIb α /VWD2 was purified on a PD-10 column (GE Healthcare) equilibrated with PBS. Radioligand concentration was determined with bicinchoninic acid assay (Pierce) with BSA as a standard. Iodination was >80% efficient. 10^5 yeast cells displaying A1 were incubated with increasing concentrations of iodinated GPIIb α /VWD2 in PBS with 1% BSA for 2 h. Samples were then centrifuged through oil (67% *n*-octyl-phthalate, 33% *n*-butyl-phthalate) (22). The samples were frozen on dry ice, and the cell pellet at the tip was cut and analyzed in a γ counter (PerkinElmer Life Sciences). Similar procedures were used for competition assays with 5–10 nM ¹²⁵I-GPIIb α /VWD2 as the probe.

Binding Analysis—Binding data were analyzed by non-linear regression using software Prism version 5.03 (GraphPad). Saturation binding data were collected alongside a negative control to determine the nonspecific binding. Both sets of data were globally fit to a one-site binding model extended by a non-specific term using Equation 1,

$$\text{Bound} = \frac{B_{\text{max}}[\text{ligand}]}{K_D + [\text{ligand}]} + \text{NS}[\text{ligand}] \quad (\text{Eq. 1})$$

Specific competition binding data were fit to a one-site model with Equations 2 and 3, where $K_{D,\text{probe}}$ was the affinity of ¹²⁵I-GPIIb α /VWD2 for that particular A1 mutant, [probe] = 5 or 10 nM depending on the experiment, and B_0 is the specific binding of the probe in the absence of the nonlabeled GPIIb α .

$$\text{Bound} = \frac{B_0}{1 + 10^{\log(\text{GPIIb}) - \log(\text{IC}_{50})}} \quad (\text{Eq. 2})$$

$$\log \text{IC}_{50} = \log \left(10^{\log K_D} \left(1 + \frac{[\text{probe}]}{K_{D,\text{probe}}} \right) \right) \quad (\text{Eq. 3})$$

Protein Crystallization and Data Collection—Proteins were in 10 mM Tris, pH 7.4, and 150 mM sodium chloride. For complexes, equimolar amounts of A1 and GPIIb α were mixed. Crystals of A1 with Y1271C and C1272R mutations (A1/SS) appeared in drops containing 25% PEG 3350 and 0.2 M calcium acetate. These crystals were crushed and used for seeding. Crystals grown in 8 mg/ml protein, 15% PEG 3350, and 0.2 M calcium acetate were harvested and soaked in the same buffer containing 20% glycerol for cryoprotection. Crystals of A1/SS-GPIIb α /VWD2 complex appeared in drops with 20% PEG 4000, 0.16 M ammonium sulfate, 0.08 M sodium acetate, pH 4.6, and 20% glycerol. These crystals were crushed and used for seeding crystal growth in 8 mg/ml complex, 15% PEG 4000, 0.16 M ammonium sulfate, 0.08 M sodium acetate, pH 4.6, and 20% glycerol. Because these crystals were formed in buffer containing 20% glycerol, no additional cryoprotection was used. Crystals of A1 with two VWD mutations R1306Q and I1309V (A1/VWD2) in complex with GPIIb α /VWD2 appeared in 12% PEG 8000, 0.1 M sodium cacodylate, pH 6.5, 0.1 M calcium acetate, and 0.4 mg/ml ristocetin (Sigma-Aldrich). These crystals were crushed and used for seeding. Crystals grew in 10 mg/ml complex, 14% PEG 8000, 0.2 M calcium acetate, 0.1 M sodium cacodylate, pH 6.5, and 0.4 mg/ml ristocetin. Next, we soaked these crystals in 14% PEG 8000, 0.2 M calcium acetate, 0.1 M sodium cacodylate, pH 6.5, and 4 mg/ml ristocetin. Data for A1/SS-GPIIb α /VWD2 were collected at 100 K at the Southeast Regional Collaborative Access Team (SER-CAT) 22-ID beamline. Data for A1/SS and A1/VWD2-GPIIb α /VWD2 were collected at 100°K at the General Medicine/Cancer (GM/CA)-CAT 23-ID beamline. Both beamlines are at the Advanced Photon Source, Argonne National Laboratory.

Structure Determination and Refinement—All data were processed with HKL-2000 or XDS. The structures were solved by molecular replacement using MOLREP (23). 1SQ0 served as the model for A1/VWD2-GPIIb α /VWD2; A1/VWD2-GPIIb α /VWD2 served as the model for A1/SS-GPIIb α /VWD2; and 1AUQ served as the search model for A1/SS. Structure refinement was performed using COOT (24) and PHENIX (25). The resolution for A1/SS-GPIIb α /VWD2 was found to extend to 2.8 Å using cross-correlation (26); we could not similarly extend resolution of the data sets for the other two crystals because their higher resolution reflections went beyond the edge of the detector. Validation and Ramachandran statistics used MOLPROBITY (27). APBS was used to calculate electrostatic surfaces (28).

RESULTS

Directed Evolution of A1 Affinity—The A1 domain of VWF was fused to the Aga2 protein in *S. cerevisiae* and expressed on the yeast surface (29). A library of greater than 10^7 random mutants was selected for high affinity for GPIIb α using several steps of isolation with magnetic activated cell sorting and FACS. Fourteen mutants were selected, most of which contained more than one mutation (Table 1). Remarkably, about half contain mutations of residues previously found to be mutated in VWD (Table 1).

The highest affinity single mutant found was Y1271C (Table 2). Mutant Y1271S was markedly lower in affinity although still

higher than wild type. This finding, together with the observation that the Y1271C mutation introduces a cysteine adjacent to Cys¹²⁷², which forms a long range disulfide bond to Cys¹⁴⁵⁸, suggested that a novel disulfide bond introduced by the mutation might be responsible for the increase in affinity. To test this possibility, we prepared Y1271C/C1272R, which could form an alternative, long range Cys¹²⁷¹ disulfide bond to Cys¹⁴⁵⁸, and Y1271C/C1458R, which could form a vicinal disulfide between Cys¹²⁷¹ and Cys¹²⁷². The latter showed GPIb α binding similar to wild type (Table 2). In contrast, Y1271C/C1272R showed a 10-fold increase in fluorescent GPIb α binding compared with the 5-fold increase in Y1271C (Table 2). These results are consistent with a mixture of Cys¹²⁷¹–Cys¹⁴⁵⁸ and Cys¹²⁷²–Cys¹⁴⁵⁸ long range disulfide bonds in Y1271C and only a Cys¹²⁷¹–Cys¹⁴⁵⁸ long range disulfide in Y1271C/C1272R. Formation of a disulfide bond in Y1271C/C1272R was confirmed by its differing migration in reducing and non-reducing SDS-PAGE (data not shown). We conclude that moving the long range disulfide bond in A1 so that it connects to residue 1271 rather than 1272 markedly increases affinity.

We quantitated affinity with saturation binding of [¹²⁵I]-G233V/M239V-GPIb α (GPIb α /VWD2). The G233V and M239V GPIb α PT-VWD mutations have previously been found to be additive or synergistic in VWF functional assays (30, 31). Competition was used to determine the affinity of A1 mutants for wild-type GPIb α and GPIb α /VWD2 (Table 2).

TABLE 1**A1 clones with high affinity for GPIb α selected by yeast surface display**

Many of the isolates contained more than one mutation. Mutations of residues known to be mutated in VWD are in boldface type, and those with the exact substitutions in VWD are additionally underlined.

Clone	A1 mutation(s)
1	L1267S/I1309T
2	I1309F
3	Y1271C/C1458R
4	C1272R
5	V1279A / <u>S1310F</u>
6	V1314A
7	R1287G /N1398I/I1410T/E1429K
8	F1270S/M1393I/K1406R
9	Y1271C/Q1388R/L1460F
10	S1378P
11	L1267S/D1269G/Y1271C/D1302A/ <u>I1309V</u> /V1409T/ K1430R/D1451G
12	R1274G/H1322R/K1332R
13	I1309T/R1426C
14	F1270S/W1313P/V1360I/Q1391R/P1465L

TABLE 2**Binding of VWF-A1 mutants to GPIb α**

Mutation	ASFI ^a for WT GPIb α	K _D for WT GPIb α ^b	K _D for GPIb α G233V/M239V (VWD2) ^b
		<i>nM</i>	<i>nM</i>
WT	1	2470 (1920–3170)	109 (70–148)
Y1271C	4.87	487 (403–589)	81.2 (44–119)
Y1271S	1.69	ND ^c	ND
C1272R	1.30	ND	ND
Y1271C/C1272R (A1/SS)	9.82	245 (170–357)	9.0 (2.6–15.3)
Y1271C/C1458R	0.95	ND	ND
C1272R/C1458R	1.00	ND	ND
R1306Q	1.71	1010 (848–1210)	83 (32–135)
I1309V	3.41	737 (651–834)	95 (42–148)
R1306Q/I1309V (A1/VWD2)	9.06	245 (214–281)	9.7 (3.7–15.7)

^a ASFI, adjusted specific fluorescence intensity; the ratio of specific GPIb α fluorescence/c-Myc tag fluorescence normalized to WT.

^b K_D values were determined by radiometric titration with [¹²⁵I]-labeled GPIb α /VWD2 and competition with unlabeled GPIb α or GPIb α /VWD2. Error is reported as 95% confidence interval.

^c ND, not determined.

Individual A1 VWD gain-of-function R1306Q and I1309V mutants showed a severalfold increase in affinity, and the double R1306Q/I1309V mutant (A1/VWD2) showed a 10-fold increase in affinity (17). Notably, the novel Y1271C/C1272R mutant (A1/SS) also showed a 10-fold increase in affinity (Table 2). The K_D values for A1/VWD2 and A1/SS were each close to 250 nM for wild-type GPIb α and 10 nM for GPIb α /VWD2 (Table 2).

Overall Crystal Structures—To investigate the structural basis for increased affinity, we determined crystal structures of GPIb α /VWD2 complexed with A1/VWD2 (2.08 Å resolution, 1 complex/asymmetric unit) (Fig. 1A), GPIb α /VWD2 complexed with A1/SS (2.8 Å resolution, 4 complexes/asymmetric unit), and for comparison, A1/SS alone (2.2 Å resolution, 2 molecules/asymmetric unit) (Table 3). Furthermore, we compare our structures with a complex with R1306Q A1 and M239V GPIb α mutations (A1/VWD1- GPIb α /VWD1, 3.1 Å, 1 complex/asymmetric unit) (12) and wild-type A1 complexed with wild-type GPIb α (A1/WT-GPIb α /WT, 2.6 Å, 1 complex/asymmetric unit) (13). A number of structures of A1 and GPIb α , either alone or complexed with other proteins, are available for comparison (Table 4).

The primary interaction between A1 and GPIb α occurs between the β -switch region of GPIb α and the central β -sheet of the A1 domain (Fig. 1A). LRR proteins contain caps over their N- and C-terminal LRR (32). The β -switch of GPIb α contains two β -strands and extends from the C-cap, which also contains α -helices and two disulfide bonds (Fig. 1, A and D). More C-terminal is an anionic region containing sulfated tyrosines that is not ordered in any complex crystal structure to date (Fig. 1D). The β -switch joins the central A1 β -sheet to form an extended β -sheet (Fig. 1A). PT-VWD mutations locate in the β -switch (Fig. 1A). The *green spheres* in Fig. 1A mark C α atom positions of the VWD G233V and M239V mutations in GPIb α /VWD2. In the N-cap of GPIb α , a disulfide-stabilized β -finger forms a second site of interaction with A1 (Fig. 1, A and B). Sites of VWD mutations in A1 (*spheres*, Fig. 1A) are located not at the A1-GPIb α interface but near the N and C termini of A1. *Red and yellow spheres* in Fig. 1A mark C α atom positions of the mutated residues in A1/VWD2 and A1/SS, respectively.

Complex structures solved in this work and previously published complex structures (12, 13) are shown superimposed on the A1 domain in Fig. 1B. Large conformational changes in the




FIGURE 1. The VWF A1-GPIIb α complex. A, overall structure in a schematic diagram. A1 (cyan) has a central β -sheet that interacts with GPIIb α (pink) by forming an extended β -sheet with the GPIIb α β -switch. A single disulfide bond in A1 and three disulfide bonds in GPIIb α are shown in yellow stick form. VWD type 2B mutations locate near the A1 termini distant from the GPIIb α interface and are shown as α spheres in red (R1306Q and I1309V type 2B mutations used in this study), silver (other 2B mutations), and yellow (Y1271C and C1272R mutations used here). PT-VWD mutations locate in the GPIIb α β -switch region (green α spheres for the G233V and M239V mutations used here). GPIIb α LRR2 to -4, shown not to bind to A1 in previous crystal structures but to be important for ristocetin and shear-induced binding to VWF (15), are shown in gray. B and C, previous and current A1-GPIIb α complexes superimposed on A1 and shown as α ribbons. Magenta, A1/VWD2-GPIIb α /VWD2; orange, A1/SS-GPIIb α /VWD2, chains E and F; yellow, chains G and H; cyan, A1/VWD1-GPIIb α /VWD1 (12), PDB code 1M10; silver, A1/WT-GPIIb α /WT (44), PDB code 1S0Q. C, the same superposition, rotated 90° to show the A1-binding face of GPIIb α with A1 removed. D and E, sequences with secondary structure overlined, GPIIb α regions marked, and decadal residues dotted. Regions present in constructs but disordered in crystals are in italic type. PT-VWD mutations used here and known VWD type 2B mutations are marked with asterisks.

A1 domain are not observed for any structure. Structural differences in A1 are restricted to the N and C termini and to the α 1- β 2 loop (Fig. 1, B and E). Differences in the orientation of GPIIb α relative to A1 are visualized by rotating the superimposed structures shown in Fig. 1B so that A1 faces the reader and then removing A1 to show the concave A1-binding face of GPIIb α (Fig. 1C). In the WT complex, GPIIb α is shifted laterally relative to complexes with high affinity mutants (*i.e.* to the right in Fig. 1C). Further differences between the structures are noted in the β -finger of GPIIb α (Fig. 1, B and C). In contrast, there is little difference in position of the β -switch when superposition is performed on A1, in agreement with the constraints

imposed by forming hydrogen bonds between the β -switch and the β -sheet in A1, and forming a large interface.

The β -Switch—The β -switch is the major binding interface between A1 and GPIIb α and also the site of PT-VWD mutations. In complex with A1, the β -switch consists of two antiparallel β -strands linked by a β -hairpin turn (12, 13) (Figs. 1A and 2A). The β -hairpin joins the central A1 β -sheet, with switch residues 237–239 forming antiparallel hydrogen bonds to A1 β -strand 3 (Fig. 2, A–C). WT and all mutant structures show identical backbone hydrogen bonds between A1 and β -switch and between the two β -switch β -strands (Fig. 2, A–C) (data not shown). The GPIIb α /VWD1 (M239V) and GPIIb α /WT com-

TABLE 3

X-ray diffraction and refinement statistics

	A1/VWD2-GPIIb/IIIa/VWD2	A1/SS	A1/SS-GPIIb/IIIa/VWD2
Data			
Space group	P6 ₁	P2 ₁	P2 ₁
Examples/asymmetric unit	1	2	4
Cell dimensions			
<i>a</i> , <i>b</i> , <i>c</i> (Å)	89.1, 89.1, 124.5	41.3, 50.1, 96.9	96.5, 103.8, 119.9
α , β , γ (degrees)	90, 90, 120	90, 92.7, 90	90, 90.1, 90
Wavelength (Å)	1.03322	1.03322	1.00000
Resolution (Å)	48.4–2.08 (2.19–2.08) ^a	50.0–2.2 (2.24–2.20) ^a	48.3–2.80 (2.87–2.80) ^a
Observations/unique	251,729/66,245	288,382/20,133	188,956/56,526
<i>I</i> / <i>s</i> overall	8.9 (1.7) ^a	13.2 (2.0) ^a	2.56 (0.3) ^a
<i>CC</i> _{1/2} ^b	NA ^c	NA	94.9 (15.6) ^a
Completeness	99.9 (99.5) ^a	99.5 (98.0) ^a	96.6 (80.9) ^a
<i>R</i> _{merge} ^d	8.9 (73.9) ^a	14.8 (53.6) ^a	58.8 (418) ^a
Structure refinement			
<i>R</i> _{work} (%) ^e	17.6	18.6	25.3
<i>R</i> _{free} (%) ^f	19.7	23.5	28.6
Protein/solvent atoms	3721/204	3234/175	14634/66
Root mean square deviation bond length (Å)	0.003	0.004	0.002
Root mean square deviation bond angle (degrees)	0.70	0.66	0.47
Ramachandran favored/allowed/outliers (%)	95.9/3.9/0.2	97.0/3.0/0	93.2/6.5/0.3
Protein Data Bank code ^g	4C2A	4C29	4C2B

^a Values in parentheses are for the highest resolution shell.^b Pearson's correlation coefficient between average intensities of random half-data sets of the measurements for each unique reflection (26).^c NA, not applicable; higher resolution reflections went beyond the edge of the detector, preventing extension of resolution using the *CC*_{1/2} criterion.^d $R_{\text{merge}} = \sum_i |I(i,h) - \langle I(i,h) \rangle| / \sum_i I(i,h)$, where $I(i,h)$ and $\langle I(i,h) \rangle$ are the *i*th and mean measurement of intensity of reflection *h*.^e $R_{\text{work}} = \sum_h ||F_{\text{obs}}(h)| - |F_{\text{calc}}(h)|| / \sum_h |F_{\text{obs}}(h)|$, where $F_{\text{obs}}(h)$ and $F_{\text{calc}}(h)$ are the observed and calculated structure factors, respectively.^f *R*_{free} is the *R*-factor for a selected subset of the reflections that are not included in refinement calculations.^g Experimental data has been deposited with the indicated deposition ID codes.

TABLE 4

Structures of A1 and GPIIb/IIIa examined

Code ^a	A1	A1 chains	GPIIb/IIIa	GPIIb/IIIa chains	Å	Additional molecules	Source/Reference
A1/VWD2-GPIIb/IIIa/VWD2	R1306Q/I1309V	A	G233V/M239V	B	2.08		This work
A1/SS-GPIIb/IIIa/VWD2	Y1271C/C1272R	A,C,E,G	G233V/M239V	B,D,F,H	2.8		This work
1M10	R1306Q	A	M239V	B	3.1		Ref. 12
1SQ0	WT	A	WT	B	2.6		Ref. 13
1U0N	WT	A	WT	D	2.95	Botrocetin	Ref. 33
A1/SS	Y1271C/C1272R	A, B			2.2		This work
1AUQ	WT	A			2.3		Ref. 10
1OAK	WT	A			2.2	Fab	Ref. 43
1U0O	WT mouse	C			2.7	Botrocetin	Ref. 33
1IJK	I1309V	A			2.6	Botrocetin	Ref. 35
1IJB	I1309V	A			1.8	Fab	Ref. 35
1FNS	I1309V	A			2.0	Fab	Ref. 34
1UEX	WT	C			2.85	Biticetin	Ref. 50
3HXO	WT	A			2.4	Aptamer	Ref. 51
3HXQ	WT	A			2.69	Aptamer	Ref. 51
1GWB			WT	A,B	2.8		Ref. 49
1M0Z			M239V	A,B	1.85		Ref. 12
1OOK			WT	G	2.3	α -Thrombin	Ref. 45
1P8V			WT	A	2.6	α -Thrombin	Ref. 44
1QYY			WT	A,G	2.8		Ref. 46
1P9A			WT	G	1.7		Ref. 45
3P72			WT	A	1.9	Peptide	Ref. 47
3PMH			WT	G	3.2	α -Thrombin	Ref. 48

^a Abbreviation or PDB accession code.

plexes show different β -hairpin turn geometries near turn residue Val²³⁴ (Fig. 2, *B* and *C*) (13); however, it is difficult to relate this to the Met to Val substitution at residue 239, which is four positions away in the β -ladder from the β -turn. In contrast, the G233V substitution in GPIIb/IIIa/VWD2 is adjacent to the β -turn (Fig. 2A). To make room for the Val²³³ side chain adjacent to the Val²³⁶ side chain, the backbone at Gln²³² and Val²³³ rotates and, together with a hydrogen bond between the Gln²³² side chain and Val²³⁴ backbone, causes a markedly different β -turn conformation (Fig. 2, *A–C*).

The Val side chain added by the G233V substitution does not interact with the A1 domain (Fig. 2A). Although the M239V substitution lies adjacent to A1, it does not markedly change the buried interface (12, 13) (Fig. 2, *B* and *C*). Residues 233 and 239

each lie in regions of the β -switch that form β -strands in A1-bound but not unliganded GPIIb/IIIa structures (Fig. 2D). Val is a β -branched side chain and favors β -strand conformation (12); however, PT-VWD mutations may also act by destabilizing the unbound state of GPIIb/IIIa (14). The finding that Val²³³ does not interact with A1 supports the concept that substitutions of β -switch residues may raise affinity by shifting the conformation of the β -switch away from that present in the unbound state and toward that present in the bound state (12, 14).

We point out here that in the unbound state of GPIIb/IIIa, Trp²³⁰ and preceding residues in the β -switch adopt a β -conformation in common with the bound state (Fig. 2D). A remarkable π -cation bond between Trp²³⁰ and LRR5 residue Lys¹³² is found in all GPIIb/IIIa structures (Fig. 2, *A–D*) and, together with nearby aro-





FIGURE 2. **The β -switch.** A–C, diagrams show C α traces with key side chains and the backbone in β -sheet regions in stick representations with carbons in cyan (A1) and pink (GPIIb α), nitrogens in blue, and oxygens in red. Hydrogen bonds in the switch region and the Lys¹³²–Trp²³⁰ π -cation bond are shown as black dashes. The structures shown are indicated in each panel. D, flexibility in the β -switch in the absence of A1. GPIIb α structures in the absence of A1 are superimposed on GPIIb α complex structures with A1. The C α atom positions of residues 233 and 239, mutated in VWD, are shown as small spheres. Structures are A1/VWD2-GPIIb α /VWD2 (magenta); A1/WT-GPIIb α /WT (44), PDB code 1SQ0 (cyan); GPIIb α /VWD1 (12), PDB code 1M0Z chain B (purple); GPIIb α /WT (45), PDB code 1P9A chain A (green); GPIIb α /WT (44), PDB code 1P8V (dark green); GPIIb α /WT (46), PDB code 1QYY chain A (orange); GPIIb α /WT PDB code 3P72 (47) (yellow); GPIIb α /WT (48), PDB code 3PMH (light green); GPIIb α /WT (49), PDB code 1GWB chain A (lavender).

matic and hydrophobic residues (Fig. 2D), stabilizes this region in β -conformation. Because GPIIb α residues Val²²⁹ and Trp²³⁰ are in β -conformation prior to A1 binding, they can act as a template for forming β -sheet hydrogen bonds to switch residues 240–238, followed by joining to the β -sheet in A1 and zipping up the remainder of the β -switch as a β -ribbon. Aromatic residues are abundant on both the A1 and GPIIb α sides of their β -sheet interface and contribute to the stability of this interface (Fig. 2, A–D).

The α 1- β 2 Loop—As already noted, when complex structures are superimposed on the A1 domain (Fig. 3A), the most notable differences in A1 are in the N and C termini and the α 1- β 2 loop (Figs. 1 (A and B) and 3 (A–C); boxed in Fig. 3A). Previous comparison of single examples in crystals of A1/WT-GPIIb α /WT and A1/VWD1-GPIIb α /VWD1 complexes demonstrated differences in the conformation of the A1 α 1- β 2 loop and suggested that this correlated with and was responsible for affinity differences (13). However, the larger number of high affinity complexes made available by this work does not support a simple correlation between α 1- β 2 loop conformation and affinity (a more complex relationship is described under “Dis-

cussion”). Multiple examples of the A1/SS-GPIIb α /VWD2 complex show an α 1- β 2 loop conformation essentially identical to that found in uncomplexed A1/WT (1AUQ; Fig. 3B). Further examples of WT-like A1 α 1- β 2 loop conformations are found in an A1-GPIIb α complex formed with botrocetin (1UON; Fig. 3B), A1 I1309V mutants (1IJK, 1IJB, and 1FNS; Fig. 3B), A1 complexes with botrocetin or biticetin (1U0O, 1IJK, and 1UEX; Fig. 3B), and A1 complexes with Fabs or an aptamer (1U0O, 1IJB, 1FNS, 3HXO, and 3HXQ; Fig. 3B). In contrast to the A1/SS-GPIIb α /VWD2 complex (and the A1/WT-GPIIb α /WT complex with botrocetin, which shows “sliding” of the A1-GPIIb α interface (33)), all other complexes show shifts of the α 1- β 2 loop from uncomplexed A1 WT (Fig. 3C). The α 1- β 2 loop conformational change is shown in Fig. 3, D–I, by a solid line connecting Gln¹³¹¹ (C α sphere) to its position in uncomplexed A1WT. In A1/VWD1-GPIIb α /VWD1, the α 1- β 2 loop is shifted slightly away from the GPIIb α interface (Fig. 3, C and G); in the A1/VWD2-GPIIb α /VWD2 complex, the loop is shifted further (Fig. 3, C and H); and in the A1/WT-GPIIb α /WT complex, the loop is shifted most and in a different direction toward the A1 termini (Fig. 3, C and I). The greater shift of the α 1- β 2

Structural Basis of VWF Binding to GPIb α






FIGURE 4. Alteration of the termini and VWD mutation-proximal region of A1 by mutations and complex formation with GPIIb α shown in stereoview. C α traces are supplemented with key side chains and hydrogen bond-forming backbone regions in stick representations. A1 side chains mutated in VWD (whether wild-type or mutated in the structures shown) have pink carbons. Nitrogen, oxygen, and sulfur are blue, red, and gold, respectively. Black dashes show key hydrogen bonds. Structures are named in A–F; A1/WT in A is PDB code 1AUQ.

loop in the WT complex relates to the different overall orientation between A1 and GPIIb α (Fig. 1, B and C). Variation in α 1- β 2 loop conformation also relates to variation in GPIIb α β -finger orientation among complexes (Figs. 1 (B and C) and 3 (C and F–I)). This variation appears to result from avoidance of clashes rather than from maintenance of specific interactions because contacts between A1 and GPIIb α β -finger residues vary markedly among the complexes (Fig. 3, F–I).

The A1 Termini—Superposition of the uncomplexed A1 domains listed in Table 4 reveals a structurally conserved pattern of hydrogen bonds that stabilize the conformation of their termini (Fig. 4A). The N-terminal end is stabilized at Cys¹²⁷², both through its long range disulfide bond and a backbone hydrogen bond to residue 1308 (Fig. 4A). The C-terminal end is stabilized by a network of backbone-backbone and backbone-side chain hydrogen bonds from Cys¹⁴⁵⁸ to Pro¹⁴⁶² (Fig. 4A).

FIGURE 3. Structural alterations near the A1 termini and α 1- β 2 loop and GPIIb α β -finger upon complex formation. A, overview of the complex in a schematic diagram. B and C, details of the region boxed in A, shown for isolated A1 domains and an A1-GPIIb α complex with little α 1- β 2 loop perturbation (B) and for all A1-GPIIb α complexes (C). Keys in A–C show the color of each structure. Superposition is on A1. D–I, stereoviews of alterations around the A1 α 1- β 2 loop and long range disulfide upon complex formation. D and E, examples of uncomplexed molecules; F–I, complexes. All superposition is on the A1 domain; additionally, in D–E, isolated GPIIb α is shown in the same orientation as in complexes. A1 has a silver C α trace and cyan side chains; GPIIb α has a wheat C α trace and magenta side chains; and nitrogen and oxygen are blue and red, respectively. In F–I, solid black lines show movements of C α atoms of selected residues from the uncomplexed structure in D to the indicated complex structure. Dashes in D and E show backbone-backbone or backbone-water hydrogen bonds discussed under “Results,” and small red spheres in E and H show waters at an opening to the hydrophobic core of the A1 domain. Structures are as indicated in the panels. Additionally, D shows PDB codes 1AUQ (A1/WT) and 1GWB (GPIIb α /WT) chain B; E shows the A1/SS structure and 3P72 (GPIIb α /WT). The latter two GPIIb α structures show examples of large divergence of β -finger orientation. Table 4 has references for structures.

VWD type 2B mutations occur in regions that neighbor the N and C termini and, with the exception of Trp¹³¹³, are distal from GPIIb α (*pink side chains*; Fig. 4, A–F). The C-terminal network of hydrogen bonds in uncomplexed A1/WT (Fig. 4A) is conserved in the A1/WT–GPIIb α /WT complex, except for minor alterations due to the Arg¹²⁷⁴ rotamer (Fig. 4B). Many of these hydrogen bonds and consistently the Pro¹⁴⁶²–Leu¹²⁷⁵ backbone hydrogen bond are also preserved in the mutant, high affinity A1–GPIIb α complexes (Fig. 4, A–E), and uncomplexed A1/SS (Fig. 4F).

Upon binding GPIIb α , more changes are evident near the A1 N terminus than C terminus. For example, the N-proximal 2.8 Å backbone hydrogen bond between Cys¹²⁷² and residue 1308 in uncomplexed WT A1 (Fig. 4A) is not seen in the WT complex (Fig. 4B), mutant complexes (Fig. 4, C–E), or A1/SS (Fig. 4F).

It is difficult to deconvolute those A1 N terminus-proximal and GPIIb α -proximal changes that are due to GPIIb α binding and those that are due to affinity-enhancing mutations; nonetheless, it is possible to deduce from the structures the effects of the mutations on their immediate A1 environment. In A1/WT, the Arg¹³⁰⁶ side chain hydrogen-bonds to the backbone of residue 1302 (Fig. 4A). In the complexes with A1/VWD1 and A1/VWD2, the mutated Gln¹³⁰⁶ side chain points in a different direction than the WT Arg¹³⁰⁶ side chain (Fig. 4, C and E). At least in the higher resolution VWD2 complex, Gln¹³⁰⁶ forms two hydrogen bonds to the Asp¹⁴⁵¹ and Arg¹⁴⁵⁰ side chains (Fig. 4C); Arg¹⁴⁵⁰ is a known site of mutation in VWD.

The I1309V mutation present in A1/VWD2 complexes is one of the most subtle VWD mutations; previous uncomplexed A1/I1309V structures showed little change in backbone or even side chain rotamer compared with wild type (34, 35). The I1309V mutation, along with R1306Q, is in the A1 α 1– β 2 loop. The A1/VWD2–GPIIb α /VWD2 complex reveals the behavior of the I1309V mutation in a complex (Fig. 3H). The smaller size of the Val¹³⁰⁹ side chain compared with Ile allows it to dive deeper into the hydrophobic core and hence closer to Met¹³⁰⁴ in the α 1-helix and Val¹³¹⁶ in the β 2-strand (Fig. 3H), compared with Ile¹³⁰⁹ in the A1/VWD1–GPIIb α /VWD1 and A1/SS–GPIIb α /VWD2 complexes (Fig. 3, F and G). However, the markedly different shape of the α 1– β 2 loop in the A1/WT–GPIIb α /WT complex allows its Ile¹³⁰⁹ to dive almost as deep as Val¹³⁰⁹ in the A1/VWD2–GPIIb α /VWD2 complex (Fig. 3I). Lack of a clear structural phenotype for Val¹³⁰⁹ in a complex structure is consistent with hypothesized further structural change to a super high affinity state (see “Discussion”).

Shifting the long range disulfide in the Y1271C/C1272R A1/SS mutant imparts greater freedom to the N terminus of A1. Cys¹²⁷¹ takes the place of Cys¹²⁷², with no significant change in the backbone and C β position of Cys¹⁴⁵⁸ and only 1-Å differences in positions of the C α and C β atoms of Cys¹²⁷¹ compared with Cys¹²⁷² (Fig. 3, D and E).

The comparisons to A1/SS reveal the Cys¹²⁷²/Cys¹⁴⁵⁸ disulfide as an important transducer of A1 conformational change upon complex formation with GPIIb α . Upon complex formation, there is no significant change in the backbone position of Cys¹⁴⁵⁸ in A1/SS (Fig. 3, E and F), whereas a 2-Å shift occurs in A1/WT, A1/VWD1, and A1/VWD2 (Fig. 3, G–I). The shift at

Cys¹⁴⁵⁸ is enforced by a shift in a similar direction at Cys¹²⁷² of >2 Å (Fig. 3, G–I). In turn, the shift at Cys¹²⁷² appears to be enforced by a subtle adjustment in the α 1– β 2 loop backbone at residues Leu¹³⁰⁷ and Arg¹³⁰⁸; the Leu¹³⁰⁷ side chain would clash with the Cys¹²⁷² side chain unless Cys¹²⁷² moved (Fig. 3, G–I). In the A1/SS–GPIIb α /VWD2 complex, Cys¹²⁷¹ moves away from Leu¹³⁰⁷ similarly to Cys¹²⁷²; however, this movement is accommodated by the extra backbone residue at 1272 in the A1/SS–GPIIb α /VWD complex and does not require movement of Cys¹⁴⁵⁸ (Fig. 3F).

The Electrostatic Interface—The calculated pI values for GPIIb α (residues 1–265) and A1 (residues 1267–1465) are 5.5 and 9.2, respectively. Furthermore, their interaction interface is highly electrostatic (12) (Fig. 5). As described above, the orientation differs between the WT complex (Fig. 5A) and the high affinity mutant complexes, exemplified by A1/VWD2–GPIIb α /VWD2 (Fig. 5B). The change in orientation shifts a cluster of six basic residues in A1 more into an acidic concave surface in GPIIb α in the high affinity complexes (note the change in position of the non-overlapping portion of the A1 backbone in Fig. 5) and increases charge complementarity. This shift is also observed for A1/SS–GPIIb α /VWD2 (Fig. 5C).

The curvature of LRR proteins varies depending on the structure and number of residues in the portion of each repeat on the convex surface (32). Furthermore, there is some inherent flexibility in a given LRR protein. The curvature of an LRR protein may be characterized by its radius of curvature or the number of degrees subtended by each LRR (32). Flexion in GPIIb α is more conveniently measured as the distance between LRR1 and LRR8 (Table 5). LRR1–LRR8 distances of 31 and 30.3 Å in the two examples of unliganded GPIIb α in the 1M0Z structure correspond to total rotations of 85.9 and 94.0° about a central axis, respectively (32). Among six high affinity complexes, this distance is 31.06 $\pm$ 0.16 Å (mean $\pm$ S.D.) (Table 5). This distance is lower in the wild-type complex and the wild-type complex with bound botrocetin, at 30.48 $\pm$ 0.02 Å (mean $\pm$ difference from mean), showing that GPIIb α in the two wild-type complexes is more concave. Among 11 independent examples of GPIIb α in isolation or in complex with peptide or α -thrombin (Table 5), the distances show much greater variation of 30.48 $\pm$ 0.48 Å. The tighter distributions of distances among the high affinity and among the wild-type complexes and the differences between the two distributions suggest that their binding modes constrain GPIIb α curvature. The greater stretch (lesser concavity) of GPIIb α in the high affinity complexes enables A1 to come closer to the concave, acidic surface of GPIIb α , increasing electrostatic attraction.

An Interaction with LRR4 and LRR5—The closer approach of A1 to the less concave surface of GPIIb α in high affinity complexes compared with the low affinity wild-type complex brings the C α position of A1 Lys¹³⁷¹ closer to acidic patch residues GPIIb α Glu¹²⁸ and Glu¹⁵¹ and nearby polar residues Thr¹⁰³ and Gln¹²⁷ (Fig. 5, D–G). No hydrogen bond across the interface of Lys¹³⁷¹ is present in the wild-type complex (Fig. 5D). The density of the Lys¹³⁷¹ side chain is weak in the previous A1/VWD1–GPIIb α /VWD1 3.1 Å complex crystal structure, and no hydrogen bond of Lys¹³⁷¹ across the interface was modeled (Fig. 5E). However, Lys¹³⁷¹ density is well defined in the 2.08 Å




FIGURE 5. Electrostatic complementarity and interaction of A1 Lys¹³⁷¹ with GPIIb α . A–C, A1-GPIIb α complexes are shown in identical orientations, with A1 in green α trace with key side chains in stick representations and GPIIb α as a solvent-accessible surface colored by electrostatics from -7 eV (red) to 0 eV (white) to 7 eV (blue). D–G, the interaction between A1 K1371 and GPIIb α . GPIIb α (silver carbons to left) and A1 (green carbons to right) are shown as α traces with relevant side chains in stick representations. Hydrogen bonds to Lys¹³⁷¹ are shown as black dashes. 2F_o - F_c electron density contoured at 1 σ is shown as orange mesh within 1.8 Å of C α , and other atoms of the side chains are shown in stick representations.

A1/VWD2-GPIIb α /VWD2 structure and demonstrates that the Lys¹³⁷¹ side chain hydrogen-bonds across the interface to Thr¹⁰³ and Gln¹²⁷ in GPIIb α LRR4 and LRR5, respectively (Fig. 5F). The 2.8 Å A1/SS-GPIIb α /VWD2 crystal provides four independent examples in the crystal lattice of complex formation. Although there is some variation in A1 Lys¹³⁷¹ side chain orientation, all four examples show hydrogen bonding across the interface to one or more of GPIIb α residues 81, 103, 127, and 128. Density is best defined in chains G and H, which show hydrogen bonding of A1 Lys¹³⁷¹ to GPIIb α residues 81 and 103 (Fig. 5G). This is the first reported A1 interaction within LRR3–LRR5, which separate the two previously reported discontinuous interfaces in GPIIb α with A1.

To test the importance of the A1 Lys¹³⁷¹ hydrogen bond to GPIIb α Thr¹⁰³ and Gln¹²⁷ without altering overall charge, we mutated Thr¹⁰³ and Gln¹²⁷ to Ala. ¹²⁵I-GPIIb α /VWD2 binding to yeast displaying A1/SS (Fig. 6A) or A1/VWD2 (Fig. 6B) was

competed with GPIIb α /WT or GPIIb α /VWD2 with or without additional alanine mutations. The T103A and Q127A mutations each substantially decreased affinity (Fig. 6, A and B). The Q127A mutation showed the greatest effect, consistent with the close proximity of Gln¹²⁷ to nearby acidic residues Glu¹²⁸ and Glu¹⁵¹.

DISCUSSION

Binding of the A1 domain of VWF to GPIIb α on platelets is important in arteriolar hemostasis and has the most interesting property of being regulated by hydrodynamic flow. Naturally occurring mutations in the A1 domain in VWD and in GPIIb α in PT-VWD have been identified that enhance A1 and GPIIb α interaction and cause disease by gain of function (3–5). Here, we have used directed evolution in yeast to identify further gain-of-function mutations. Moving the long range disulfide bond to encompass one more residue with the Y1271C/C1272R

TABLE 5**GPIIb α curvature measured as LRR1 to LRR8 distance**

The distance between LRR1 and LRR8 in GPIIb α is measured as a surrogate for curvature (curvature increases as distance decreases) (32). All distances are given in Å.

Structure	LRR1–LRR8 C α atom distances			Average C α distance
	35–199	36–200	37–201	
	Å			Å
A1/VWD2–GPIIb α /VWD2	29.9	32.3	30.7	31.0
A1/VWD1–GPIIb α /VWD1	29.9	32.1	30.7	30.9
A1/SS–GPIIb α /VWD2, B	30.3	32.8	30.9	31.3
A1/SS–GPIIb α /VWD2, D	30.1	32.5	30.7	31.1
A1/SS–GPIIb α /VWD2, F	30.1	32.4	30.8	31.1
A1/SS–GPIIb α /VWD2, H	29.9	32.4	30.5	30.9
A1/WT–GPIIb α /WT	29.4	31.9	30.2	30.5
A1/WT–GPIIb α /WT–botrocetin	29.5	31.7	30.2	30.5
1M0Z, B	29.1	31.8	30	30.3
1M0Z, A	30	32.4	30.7	31.0
1OOK	29.6	31.9	30.1	30.5
1P8V	30.2	32.5	30.7	31.1
1P9A	29	31.6	29.8	30.1
1QYY, A	28.8	31.4	29.6	29.9
1QYY, B	28.5	31.1	29.6	29.7
3P72	29.5	32.1	30.3	30.6
3PMH	29.5	31.8	30.3	30.5
1GWB, B	29.4	32.2	30.3	30.6
1GWB, A	29.6	32.1	30.2	30.6
Average in high affinity complexes $\pm$ S.D.				31.06 $\pm$ 0.16
Average in the absence of A1 association $\pm$ S.D.				30.48 $\pm$ 0.43
Average in wild type A1 complexes $\pm$ difference from mean				30.48 $\pm$ 0.02

mutation (A1/SS) increased affinity for GPIIb α by 10-fold, similarly to the combined effect of two independent VWD mutations, R1306Q and I1309V (A1/VWD2).

We determined multiple crystal structures that extend the resolution of complexes containing VWD mutations from 3.1 to 2.08 Å and extend structural knowledge to complexes with different mutations and with markedly higher affinity. Furthermore, we now have a set of three high affinity mutant complexes (not counting independent lattice environments) in contrast to the single previous example for comparison with the wild-type complex. GPIIb α with the double G233V/M239V mutation is much more active than either single mutation alone in binding to VWF (30, 36). This is in agreement with measurement here of 25-fold higher affinity of G233V/M239V than WT and previous measurements of 3-fold higher affinity of M239V than WT (12). The R1306Q/I1309V double mutant (A1/VWD2) showed 10-fold higher affinity than WT, as did the A1/SS mutant, whereas single R1306Q and I1309V substitutions increased affinity severalfold, in agreement with a report of a 2.5-fold increase for the R1306Q mutation (12). Altogether, our complexes of A1/SS or A1/VWD2 with GPIIb α /VWD2 show a 250-fold increase in affinity relative to WT, compared with the 7.5-fold increase in affinity of the A1/VWD1–GPIIb α /VWD1 complex used previously for crystallization (12).

Despite the markedly higher affinity of the two types of double mutant complexes crystallized here, all mutant complexes show remarkably similar orientations between A1 and GPIIb α . This high affinity orientation differs from that seen in the wild-type complex, both in terms of having less concavity in GPIIb α and allowing LRR4 and LRR5 to approach closer to A1 and in allowing lateral sliding of A1 over the concave GPIIb α surface




FIGURE 6. Mutational importance of GPIIb α middle LRRs in binding A1 in high affinity complexes. A and B, 125 I–GPIIb α /VWD2 binding to A1/SS (A) or A1/VWD2 (B) displayed on yeast was competed with unlabeled GPIIb α proteins as labeled. The K_d values (95% confidence interval) measured in A are as follows: GPIIb α /WT = 317 nM (270–365), GPIIb α /VWD2 = 1.98 nM (1.78–2.21), GPIIb α /VWD2–Q127A = 63.5 nM (57.0–70.8), and GPIIb α /VWD2–T103A = 6.2 nM (5.60–6.87). The K_d values (95% confidence interval) measured in B are as follows: GPIIb α /WT = 307.5 nM (241–393), GPIIb α /VWD2 = 2.97 nM (2.70–3.26), GPIIb α /VWD2–Q127A = 35.0 nM (27.6–44.4), and GPIIb α /VWD2–T103A = 16.0 nM (14.3–18.0). Error bars, S.D.

with better electrostatic complementarity. A caveat is that we only have one example thus far of the WT complex in crystals.

The closer approach to A1 at LRR4 and LRR5 in the high affinity complexes is consistent with previous evidence implicating this region in shear-regulated increased adhesiveness of GPIIb α for VWF (15). LRR3 to –5 were previously shown to be required for ristocetin-stimulated binding of VWF to platelets (16). Ristocetin is a glycopeptide antibiotic that adventitiously activates VWF binding and is used to measure VWF function in the diagnosis of VWD. VWD type 2B mutations, two of which were used here in the A1/VWD2 mutant, reduce the concentration of ristocetin required for VWF to bind platelets (37). It is widely believed that ristocetin mimics the effect of shear on VWF (38). Ristocetin has been shown to bind to residues in the N and C terminus of A1 (39). The observations on the importance of LRR3 to –5 in ristocetin-stimulated binding were made by substituting canine for human sequence in this region of GPIIb α , followed by expression in CHO cells co-transfected with the associating GPIIb β and GPIX subunits (16). Subsequently, the same chimeras were examined for shear-dependent interaction of transfectants with VWF. Remarkably, as shear was increased, having human rather than canine LRR3 to –5 was increasingly important (15).

For the first time, we observed a structural interaction in this region, between Thr¹⁰³ and Gln¹²⁷ of GPIIb/IIIa and Lys¹³⁷¹ of A1. Furthermore, we demonstrated by mutation that Thr¹⁰³ and Gln¹²⁷ are important for high affinity for A1. We examined conservation of these residues in humans, canines, mice, rats, pigs, cows, and chickens. Lys¹³⁷¹ is conserved as Lys or Arg in VWF in all of these species. Gln¹²⁷ is similarly conserved as Gln or Glu in GPIIb/IIIa in the same species; however, canine is the exception with a His residue, possibly explaining the poor performance of human-canine chimeric GPIIb/IIIa in ristocetin-stimulated adhesion and in adhesion at high shear to VWF (15, 16).

The previous functional assays using canine-human GPIIb/IIIa chimeras, together with a closer approach in LRR of high affinity complexes, and our mutational studies suggest that the high affinity complexes are on a pathway toward the high affinity state induced by shear flow. An increase in shear flow to supra-physiologic levels, as well as transition of shear flow to elongational flow at sites of vasoconstriction in hemostasis, will induce an overall change in VWF concatemer shape from bird's nest to extended and therefore expose multiple A1 domains in VWF for multimeric binding to GPIIb/IIIa on platelets (5, 7). The A1 domain is flexibly connected to the neighboring D'D3 assembly and to the A2 domain by highly flexible, O-glycosylated mucin-like linkers (40). After elongation of VWF, tensile force applied by hydrodynamic flow to VWF concatemers will be communicated through the flexible linkers between domains (9) to the structured portions of the A1 domain that lie N- and C-terminal of its long range disulfide bond. These are the regions in which many VWD mutations are found and in which rearrangements occur in A1 in both high affinity and WT complexes, relative to uncomplexed A1. The hydrodynamic force exerted on the A1 N and C termini could potentially have much larger effects on A1 structure than seen here as a consequence of mutation and complex formation. Moreover, this force would increase after platelet binding to the A1 domain in VWF, as a consequence of the additional hydrodynamic force on the platelet.

Such forces might induce large scale conformational rearrangements in A1, as are seen in the VWA folds present in integrin α I and β I domains. The presence of long range disulfide bonds does not prevent conformational change in VWA domains, as illustrated by the 15-Å movement of the long range disulfide in the VWA domain of a sporozoite adhesin (41). In integrin I domains, a force exerted in a similar C-terminal direction on the C-terminal α -helix induces axial pistoning of this helix that leads to a large increase in affinity for ligand (11). Integrin I domains and the A1 domain differ greatly in the location of their ligand-binding sites, and any hypothetical large scale rearrangements in A1 would necessarily affect affinity through a different mechanism than in integrins. Above, we have argued that high affinity mutant complexes studied here and previously are on-pathway to a super high affinity A1-GPIIb/IIIa state induced by force; however, so as not to discourage further research in this area, it is important to operate under the hypothesis that the force-induced super high affinity state of the A1-GPIIb/IIIa complex has not yet been seen by crystallography.

There are several reasons to think that a high affinity, force-extended state of A1-GPIIb/IIIa has not been seen in the current study. The PT-VWD mutations in GPIIb/IIIa used here are thought to increase the propensity for β -strand formation in the β -switch (12) and, like other PT-VWD mutations, may also destabilize the unliganded conformation of the β -switch relative to the ligand-bound conformation (14). We hypothesize that the β -switch has the same conformation in complexes in the presence and absence of force; thus, PT-VWD mutations would not shift the equilibrium between these types of complexes. VWD mutations in A1 locate in or proximal to regions where force would be exerted physiologically and where shape shifting might occur; these mutations are thus hypothesized to shift the equilibrium to the high affinity state. In integrins, co-crystallization with ligand is sufficient to induce the high affinity state, and this state is even sometimes glimpsed fortuitously in a crystal lattice-dependent manner (11). However, single molecule experiments suggest that A1-GPIIb/IIIa binding is not sufficient to induce a high affinity, extended state and that this state requires a force over 10 pN to be exerted on the N terminus of A1 and the C terminus of GPIIb/IIIa and across the receptor-ligand complex (8). It is currently not possible to mimic such a force in a crystallization experiment. Our VWD R1306Q and I1309V mutations may have lowered the energy to reach such a high affinity state; however, in contrast to one report (42), we find in single molecule experiments with R1306Q and M239V mutations that two states are still observed.⁴ Ristocetin selectively strengthens the state seen in high force in single molecule experiments (8). The best-diffracting A1/VWD2-GPIIb/IIIa/VWD2 crystal selected for refinement here was crystallized in the presence of 0.4 mg/ml ristocetin and was further soaked with 4 mg/ml ristocetin. However, we found no electron density for a bound ristocetin, suggesting either that the state we have crystallized is not that stabilized by ristocetin or that lattice contacts prevented ristocetin binding.

Overall, comparisons among complexes and with uncomplexed A1 suggest that strain in VWD mutation-proximal regions occurs in both wild-type and mutant A1-GPIIb/IIIa complexes. The long range disulfide bond moves at the Cys¹²⁷² or Cys¹²⁷¹ backbone in all complexes and at the Cys¹⁴⁵⁸ backbone except in the Cys¹²⁷¹ mutant A1/SS complex. The hydrophobic cavity between the wild-type disulfide and the core of the A1 domain is sealed by a backbone hydrogen bond between Arg¹³⁰⁸ and Cys¹²⁷² in wild-type A1 (Fig. 3D). The cavity becomes exposed to water in the A1/SS mutant, in which a water replaces residue 1272 in hydrogen bonding to the Arg¹³⁰⁸ backbone (Fig. 3E). The movement of the disulfide upon binding GPIIb/IIIa appears to be transmitted from N-terminal-proximal portions of A1 that contact GPIIb/IIIa near its β -finger (Fig. 3, F–I). The dislocation of the disulfide opens up a cavity at the position vacated by Cys¹²⁷². In the high resolution A1/VWD2-GPIIb/IIIa/VWD2 complex, water also gains access to the interface between the disulfide and A1 core (Fig. 3H). Similarly, a cavity formed by the I1309V mutation is occupied by a water (43). Burial of waters in hydrophobic cavities is energetically unfavorable and thus a symptom of strain.

⁴ J. Kim, N. Hudson, and T. A. Springer, unpublished observations.

Movement of the long range disulfide appears to result from movement of contacting residue Leu¹³⁰⁷ at the end of the α 1-helix (Fig. 3, D–I). The α 1- β 2 loop neighbors Leu¹³⁰⁷, contains the R1306Q and I1309V VWD mutations studied here in addition to Trp¹³¹³, and has been extensively discussed previously with respect to a role in affinity regulation (44). The α 1- β 2 loop occupies multiple conformations in the different structures. Compared with uncomplexed A1, the position of the Ca atom of residue Q1311 in the α 1- β 2 loop varies only slightly in A1/SS-GPIb α /VWD (0.7 Å), more in A1/VWD1-GPIb α /VWD1 (1.7 Å), greatly in A1/VWD2-GPIb α /VWD2 (4 Å), and severely with an overall different loop conformation in A1/WT-GPIb α /WT (7.5 Å) (Fig. 3, D and F–I). The β -finger is variable in conformation in isolated GPIb α structures (Fig. 3, D and E) and is sometimes disordered (see structures listed in Table 4).

Remarkably, upon A1-GPIb α binding, Leu¹³⁰⁷, Ile¹³⁰⁹ in the α 1/ β 2 loop, and Cys¹²⁷² (or Cys¹²⁷¹) in the long range disulfide in A1 move in a similar direction away from GPIb α , despite the many different conformations of the contact sites in the α 1- β 2 loop and β -finger (Fig. 3, G–I). These results are consistent with a clash, rather than a favorable binding interaction, in the α 1- β 2 loop and β -finger region. Clashes can be avoided by different types of structural rearrangements, whereas favorable interactions generally result in a single type of binding interface. The overall binding interaction between A1 and GPIb α appears to be largely driven by β -sheet formation and burial of hydrophobic and aromatic groups around the β -switch and electrostatic complementarity at the A1 interface with the concave LRR surface of GPIb α . None of the binding interfaces between the α 1- β 2 loop and β -finger region show notable burial of hydrophobic residues or favorable hydrogen bond or electrostatic complementarity (Fig. 3, F–I).

In summary, the structures described here markedly advance our understanding of high affinity A1-GPIb α complexes. Strain appears to be induced in the α 1- β 2 loop, long range disulfide, and VWD mutation-containing regions of A1 upon binding at the interface between the A1 α 1- β 2 loop and GPIb α β -finger. We hypothesize that a large conformational change in these regions could dissipate this strain and reshape A1 to form a complementary interface possibly extending across the concave GPIb α surface. For these reasons, we wish to keep alive the hypothesis that in structures crystallized to date, the A1-GPIb α complex has not yet reached a hypothesized VWD mutation-facilitated, force-extended, high affinity conformation.

Acknowledgments—We thank A. Koksai and J. Zhu for discussion and crystallographic data acquisition. We thank K. D. Wittrup and K. von Hoorelbeke for reagents and K. Ketman (IDI Flow Cytometry Core) for help with FACS.

REFERENCES

- Sadler, J. E. (2005) New concepts in von Willebrand disease. *Annu. Rev. Med.* **56**, 173–191
- Wagner, D. D. (1990) Cell biology of von Willebrand factor. *Annu. Rev. Cell Biol.* **6**, 217–246
- Sadler, J. E. (1998) Biochemistry and genetics of von Willebrand factor. *Annu. Rev. Biochem.* **67**, 395–424
- Ruggeri, Z. M., and Mendolicchio, G. L. (2007) Adhesion mechanisms in platelet function. *Circ. Res.* **100**, 1673–1685
- Springer, T. A. (2011) Biology and physics of von Willebrand factor concatamers. *J. Thromb. Haemost.* **9**, 130–143
- Savage, B., Saldívar, E., and Ruggeri, Z. M. (1996) Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. *Cell* **84**, 289–297
- Schneider, S. W., Nuschele, S., Wixforth, A., Gorzelanny, C., Alexander-Katz, A., Netz, R. R., and Schneider, M. F. (2007) Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 7899–7903
- Kim, J., Zhang, C. Z., Zhang, X., and Springer, T. A. (2010) A mechanically stabilized receptor-ligand flex-bond important in the vasculature. *Nature* **466**, 992–995
- Zhang, X., Halvorsen, K., Zhang, C. Z., Wong, W. P., and Springer, T. A. (2009) Mechanoenzymatic cleavage of the ultralarge vascular protein, von Willebrand factor. *Science* **324**, 1330–1334
- Emsley, J., Cruz, M., Handin, R., and Liddington, R. (1998) Crystal structure of the von Willebrand factor A1 domain and implications for the binding of platelet glycoprotein Ib. *J. Biol. Chem.* **273**, 10396–10401
- Luo, B.-H., Carman, C. V., and Springer, T. A. (2007) Structural basis of integrin regulation and signaling. *Annu. Rev. Immunol.* **25**, 619–647
- Huizinga, E. G., Tsuji, S., Romijn, R. A., Schiphorst, M. E., de Groot, P. G., Sixma, J. J., and Gros, P. (2002) Structures of glycoprotein Iba and its complex with von Willebrand factor A1 domain. *Science* **297**, 1176–1179
- Dumas, J. J., Kumar, R., McDonagh, T., Sullivan, F., Stahl, M. L., Somers, W. S., and Mosyak, L. (2004) Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Iba complex reveals conformation differences with a complex bearing von Willebrand disease mutations. *J. Biol. Chem.* **279**, 23327–23334
- Othman, M., Kaur, H., and Emsley, J. (2013) Platelet-type von Willebrand disease. New insights into the molecular pathophysiology of a unique platelet defect. *Semin. Thromb. Hemost.* **39**, 663–673
- Shen, Y., Cranmer, S. L., Aprico, A., Whisstock, J. C., Jackson, S. P., Berndt, M. C., and Andrews, R. K. (2006) Leucine-rich repeats 2–4 (Leu⁶⁰–Glu¹²⁸) of platelet glycoprotein Iba regulate shear-dependent cell adhesion to von Willebrand factor. *J. Biol. Chem.* **281**, 26419–26423
- Shen, Y., Romo, G. M., Dong, J. F., Schade, A., McIntire, L. V., Kenny, D., Whisstock, J. C., Berndt, M. C., López, J. A., and Andrews, R. K. (2000) Requirement of leucine-rich repeats of glycoprotein (GP) Iba for shear-dependent and static binding of von Willebrand factor to the platelet membrane GP Ib-IX-V complex. *Blood* **95**, 903–910
- Miura, S., Li, C. Q., Cao, Z., Wang, H., Wardell, M. R., and Sadler, J. E. (2000) Interaction of von Willebrand factor domain A1 with platelet glycoprotein Iba-(1–289). Slow intrinsic binding kinetics mediate rapid platelet adhesion. *J. Biol. Chem.* **275**, 7539–7546
- Mi, L. Z., Grey, M. J., Nishida, N., Walz, T., Lu, C., and Springer, T. A. (2008) Functional and structural stability of the epidermal growth factor receptor in detergent micelles and phospholipid nanodiscs. *Biochemistry* **47**, 10314–10323
- Cauwenberghs, N., Vanhoorelbeke, K., Vauterin, S., Westra, D. F., Romo, G., Huizinga, E. G., Lopez, J. A., Berndt, M. C., Harsfalvi, J., and Deckmyn, H. (2001) Epitope mapping of inhibitory antibodies against platelet glycoprotein Iba reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Iba. *Blood* **98**, 652–660
- Zaccolo, M., Williams, D. M., Brown, D. M., and Gherardi, E. (1996) An approach to random mutagenesis of DNA using mixtures of triphosphate derivatives of nucleoside analogues. *J. Mol. Biol.* **255**, 589–603
- Chao, G., Lau, W. L., Hackel, B. J., Sazinsky, S. L., Lippow, S. M., and Wittrup, K. D. (2006) Isolating and engineering human antibodies using yeast surface display. *Nat. Protoc.* **1**, 755–768
- Schürpf, T., and Springer, T. A. (2011) Regulation of integrin affinity on cell surfaces. *EMBO J.* **30**, 4712–4727
- Vagin, A., and Teplyakov, A. (2010) Molecular replacement with MOLREP. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 22–25
- Emsley, P., and Cowtan, K. (2004) Coot. Model-building tools for molecular graphics. *Acta Crystallogr. D Biol. Crystallogr.* **60**, 2126–2132
- Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols,

- N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: A comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 213–221
26. Karplus, P. A., and Diederichs, K. (2012) Linking crystallographic model and data quality. *Science* **336**, 1030–1033
27. Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., 3rd, Snoeyink, J., Richardson, J. S., and Richardson, D. C. (2007) MolProbity: All-atom contacts and structure validation for proteins and nucleic acids. *Nucleic Acids Res.* **35**, W375–W383
28. Baker, N. A., Sept, D., Joseph, S., Holst, M. J., and McCammon, J. A. (2001) Electrostatics of nanosystems. Application to microtubules and the ribosome. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 10037–10041
29. Boder, E. T., and Wittrup, K. D. (1997) Yeast surface display for screening combinatorial polypeptide libraries. *Nat. Biotechnol.* **15**, 553–557
30. Tait, A. S., Cranmer, S. L., Jackson, S. P., Dawes, I. W., and Chong, B. H. (2001) Phenotype changes resulting in high-affinity binding of von Willebrand factor to recombinant glycoprotein Ib-IX. Analysis of the platelet-type von Willebrand disease mutations. *Blood* **98**, 1812–1818
31. Flood, V. H., Friedman, K. D., Gill, J. C., Morateck, P. A., Wren, J. S., Scott, J. P., and Montgomery, R. R. (2009) Limitations of the ristocetin cofactor assay in measurement of VWF function. *J. Thromb. Haemost.* **7**, 1832–1839
32. Enkhbayar, P., Kamiya, M., Osaki, M., Matsumoto, T., and Matsushima, N. (2004) Structural principles of leucine-rich repeat (LRR) proteins. *Proteins* **54**, 394–403
33. Fukuda, K., Doggett, T., Laurenzi, I. J., Liddington, R. C., and Diacovo, T. G. (2005) The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation. *Nat. Struct. Mol. Biol.* **12**, 152–159
34. Celikel, R., Ruggeri, Z. M., and Varughese, K. I. (2000) von Willebrand factor conformation and adhesive function is modulated by an internalized water molecule. *Nat. Struct. Biol.* **7**, 881–884
35. Fukuda, K., Doggett, T. A., Bankston, L. A., Cruz, M. A., Diacovo, T. G., and Liddington, R. C. (2002) Structural basis of von Willebrand factor activation by the snake toxin botrocetin. *Structure* **10**, 943–950
36. Flood, V. H., Gill, J. C., Morateck, P. A., Christopherson, P. A., Friedman, K. D., Haberichter, S. L., Branchford, B. R., Hoffmann, R. G., Abshire, T. C., Di Paola, J. A., Hoots, W. K., Leissinger, C., Lusher, J. M., Ragni, M. V., Shapiro, A. D., and Montgomery, R. R. (2010) Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. *Blood* **116**, 280–286
37. Dong, J. F., Berndt, M. C., Schade, A., McIntire, L. V., Andrews, R. K., and López, J. A. (2001) Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions. *Blood* **97**, 162–168
38. Ginsburg, D., and Sadler, J. E. (1993) von Willebrand disease. A database of point mutations, insertions, and deletions. For the Consortium on von Willebrand Factor Mutations and Polymorphisms, and the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. *Thromb. Haemost.* **69**, 177–184
39. De Luca, M., Facey, D. A., Favaloro, E. J., Hertzberg, M. S., Whisstock, J. C., McNally, T., Andrews, R. K., and Berndt, M. C. (2000) Structure and function of the von Willebrand factor A1 domain. Analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation. *Blood* **95**, 164–172
40. Zhou, Y. F., Eng, E. T., Nishida, N., Lu, C., Walz, T., and Springer, T. A. (2011) A pH-regulated dimeric bouquet in the structure of von Willebrand factor. *EMBO J.* **30**, 4098–4111
41. Song, G., Koksai, A. C., Lu, C., and Springer, T. A. (2012) Shape change in the receptor for gliding motility in plasmodium sporozoites. *Proc. Natl. Acad. Sci. U.S.A.* **109**, 21420–21425
42. Yago, T., Lou, J., Wu, T., Yang, J., Miner, J. J., Coburn, L., López, J. A., Cruz, M. A., Dong, J. F., McIntire, L. V., McEver, R. P., and Zhu, C. (2008) Platelet glycoprotein Ib α forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. *J. Clin. Invest.* **118**, 3195–3207
43. Celikel, R., Varughese, K. I., Madhusudan, Yoshioka, A., Ware, J., and Ruggeri, Z. M. (1998) Crystal structure of the von Willebrand factor A1 domain in complex with the function blocking NMC-4 Fab. *Nat. Struct. Biol.* **5**, 189–194
44. Dumas, J. J., Kumar, R., Seehra, J., Somers, W. S., and Mosyak, L. (2003) Crystal structure of the GPIIb/IIIa-thrombin complex essential for platelet aggregation. *Science* **301**, 222–226
45. Celikel, R., McClintock, R. A., Roberts, J. R., Mendolicchio, G. L., Ware, J., Varughese, K. I., and Ruggeri, Z. M. (2003) Modulation of α -thrombin function by distinct interactions with platelet glycoprotein Ib α . *Science* **301**, 218–221
46. Varughese, K. I., Ruggeri, Z. M., and Celikel, R. (2004) Platinum-induced space-group transformation in crystals of the platelet glycoprotein Ib α N-terminal domain. *Acta Crystallogr. D Biol. Crystallogr.* **60**, 405–411
47. McEwan, P. A., Andrews, R. K., and Emsley, J. (2009) Glycoprotein Ib α inhibitor complex structure reveals a combined steric and allosteric mechanism of von Willebrand factor antagonism. *Blood* **114**, 4883–4885
48. Zarpellon, A., Celikel, R., Roberts, J. R., McClintock, R. A., Mendolicchio, G. L., Moore, K. L., Jing, H., Varughese, K. I., and Ruggeri, Z. M. (2011) Binding of α -thrombin to surface-anchored platelet glycoprotein Ib α sulfotyrosines through a two-site mechanism involving exosite I. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 8628–8633
49. Uff, S., Clemetson, J. M., Harrison, T., Clemetson, K. J., and Emsley, J. (2002) Crystal structure of the platelet glycoprotein Ib α N-terminal domain reveals an unmasking mechanism for receptor activation. *J. Biol. Chem.* **277**, 35657–35663
50. Maita, N., Nishio, K., Nishimoto, E., Matsui, T., Shikamoto, Y., Morita, T., Sadler, J. E., and Mizuno, H. (2003) Crystal structure of von Willebrand factor A1 domain complexed with snake venom, bitiscetin. Insight into glycoprotein Ib α binding mechanism induced by snake venom proteins. *J. Biol. Chem.* **278**, 37777–37781
51. Huang, R. H., Fremont, D. H., Diener, J. L., Schaub, R. G., and Sadler, J. E. (2009) A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1. *Structure* **17**, 1476–1484